U S Physical Therapy Inc: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 8, 2022 and accepted by EDGAR at Nov 8, 2022, 14:30 ET.
Management's discussion and analysis
As filed, 61,472 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2021 filed with the Securities and Exchange Commission (the “SEC”) on March 1, 2022 (“2021 Annual Report”); and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2021 Annual Report. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and in Part II, Item 1A. Risk Factors of this report.
References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.
EXECUTIVE SUMMARY
Our Business
We operate outpatient physical therapy clinics that provide pre- and post-operative care and treatment for a variety of orthopedic-related disorders and sports-related injuries, neurologically-related injuries and rehabilitation of injured workers. We also operate an industrial injury prevention services (“IIPS”) business which includes onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments services.
Selected Operating and Financial Data
Our reportable segments include the physical therapy operations segment and the IIPS segment. Our physical operations consist of physical therapy and occupational therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventive care, rehabilitation of injured workers and neurological injuries. Services provided by the IIPS segment include onsite injury prevention and rehabilitation, performance optimization and ergonomic assessments.
On September 30, 2022, we operated 614 clinics in 40 states. In addition to our ownership and operation of outpatient physical therapy clinics, we also manage physical therapy facilities for third parties, such as physicians and hospitals, with 40 such third-party facilities under management as of September 30, 2022.
During the 2021 year and for the nine months ended September 30, 2022, we completed the acquisitions of six multi-clinic practices and two IIPS businesses as detailed below.
| Acquisition | Date | Acquired | Clinics |
|---|---|---|---|
| September 2022 Acquisition | September 30, 2022 | 80% | 2 |
| August 2022 Acquisition | August 31, 2022 | 70% | 6 |
| March 31, 2022 | March 31, 2022 | 70% | 6 |
| December 2021 Acquisition | December 31, 2021 | 75% | 3 |
| November 2021 Acquisition | November 30, 2021 | 70% | IIPS |
| September 2021 Acquisition | September 30, 2021 | 100% | IIPS |
| June 2021 Acquisition | June 30, 2021 | 65% | 8 |
| March 2021 Acquisition | March 31, 2021 | 70% | 6 |
During the nine months ended September 30, 2022, we closed five clinics and sold five clinics.
Employees
Our strategy is to acquire physical therapy practices, develop outpatient physical therapy clinics as satellites within existing partnerships, acquire IIPS businesses, and support the growth of our existing businesses, which requires a talented workforce. As of September 30, 2022, we employed approximately 6,046 people nationwide, of which approximately 3,507 were full-time employees.
It is crucial that we continue to attract and retain top talent. To attract and retain talented employees, we strive to make our corporate office and all our practices and businesses a diverse and healthy workplace, with opportunities for our employees to receive continuing education, skill development, encouragement to grow and develop their career, all supported by competitive compensation, incentives, and benefits. Our clinical professionals are all licensed and a vast majority have advanced degrees. Our operational leadership teams have long-standing relationships with local and regional universities, professional affiliations, and other applicable sources that provide our practices with a talent pipeline.
We provide competitive compensation and benefits programs to help meet our employees’ needs in the practices and communities in which they serve. These programs (which can vary by practice and employment classification) include incentive compensation plans, a 401(k) plan, healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, family leave, education assistance, mental health, and other employee assistance benefits.
We invest resources to develop the talent needed to support our business strategy. Resources include a multitude of training and development programs delivered internally and externally, online and instructor-led, and on-the-job learning formats.
We expect to continue adding personnel in the future as we focus on potential acquisition targets and organic growth opportunities.
RESULTS OF OPERATIONS
For the three months ended September 30, 2022 (“2022 Third Quarter”), our net income attributable to our shareholders was $9.6 million as compared to $10.0 million for the three months ended September 30, 2021 (“2021 Third Quarter”). In accordance with Generally Accepted Accounting Principles (“GAAP”), the revaluation of redeemable non-controlling interest, net of taxes, is not included in net income but charged directly to retained earnings; however, the charge for this change is included in the earnings per basic and diluted share calculation. Inclusive of the charge for revaluation of non-controlling interest, net of taxes, the amount is $9.4 million, or $0.72 per diluted share, for the 2022 Third Quarter, and $8.5 million, or $0.66 per diluted share, for the 2021 Third Quarter. The 2022 Third Quarter included a change in the fair value of a contingent earn-out payment which had the effect of increasing net income by $1.5 million and included a gain on revaluation of a put-right liability which increased net income by $0.6 million, both net of tax.
For the 2022 Nine Months, our net income attributable to our shareholders was $29.6 million for the 2022 Nine Months and $30.6 million for 2021 Nine Months. Inclusive of the charge for revaluation of non-controlling interest, net of taxes, the amount is $29.4 million, or $2.27 per diluted share, for the 2022 Nine Months, and $21.8 million, or $1.69 per diluted share, for the 2021 Nine Months. The 2022 Nine Months included a change in the fair value of a contingent earn-out payment which had the effect of increasing net income by $1.5 million, net of tax.
For the 2022 Third Quarter, our Operating Results, a non-GAAP measure, was $7.5 million, or $0.58 per diluted share, as compared to $10.0 million, or $0.78 per diluted share, for the 2021 Third Quarter.
For the 2022 Nine Months, our Operating Results, a non-GAAP measure, was $27.5 million, or $2.12 per diluted share, as compared to $30.6 million, or $2.37 per diluted share, for the 2021 Nine Months.
Operating Results, equals net income attributable to USPH shareholders per the consolidated statements of income less the change in the revaluation of the put-right liability and the change in the fair value of a contingent earn-out payment. In accordance with GAAP, the revaluation of redeemable non-controlling interest, net of tax, is included in the earnings per basic and diluted share calculation, although it is not included in net income but charged directly to retained earnings.
We believe providing Operating Results is useful to investors for comparing our period-to-period results and for comparing with other similar businesses since most do not have redeemable instruments and therefore have different equity structures. We use Operating Results, which eliminates certain items described above that can be subject to volatility and unusual costs, as one of the principal measures to evaluate and monitor financial performance.
Operating Results is not a measure of financial performance under GAAP and should not be considered in isolation or as an alternative to, or substitute for, net income attributable to our shareholders presented in the consolidated financial statements.
The following tables provide detail of the diluted earnings per share computation and reconcile net income attributable to our shareholders calculated in accordance with GAAP to Operating Results (in thousands, except per share data):
| Computation of earnings per share - USPH shareholders: | Three Months Ended September 30, 2022 | 2021 |
|---|---|---|
| Net income attributable to USPH shareholders | $9,557 | $10,009 |
| Charges to retained earnings: | ||
| Revaluation of redeemable non-controlling interest | (196) | (2,070) |
| Tax effect at statutory rate (federal and state) of 25.55% | 50 | 529 |
| $9,411 | $8,468 | |
| Earnings per share (basic and diluted) | $0.72 | $0.66 |
| Adjustments: | ||
| Change in revaluation of put-right liability | (785) | - |
| Change in fair value of contingent earn-out consideration | (2,000) | - |
| Revaluation of redeemable non-controlling interest | 196 | 2,070 |
| Tax effect at statutory rate (federal and state) | 661 | (529) |
| Operating Results (a non-GAAP measure) | $7,483 | $10,009 |
| Basic and diluted Operating Results per share (a non-GAAP measure) | $0.58 | $0.78 |
| Shares used in computation - basic and diluted | 13,001 | 12,909 |
| Computation of earnings per share - USPH shareholders: | Nine Months Ended September 30, 2022 | 2021 |
|---|---|---|
| Net income attributable to USPH shareholders | $29,551 | $30,618 |
| Credit (charges) to retained earnings: | ||
| Revaluation of redeemable non-controlling interest | (193) | (11,889) |
| Tax effect at statutory rate (federal and state) of 25.55% | 49 | 3,038 |
| $29,407 | $21,767 | |
| Earnings per share (basic and diluted) | $2.27 | $1.69 |
| Adjustments: | ||
| Change in revaluation of put-right liability | (771) | - |
| Change in fair value of contingent earn-out consideration | (2,000) | - |
| Revaluation of redeemable non-controlling interest | 193 | 11,889 |
| Tax effect at statutory rate (federal and state) | 659 | (3,038) |
| Operating Results (a non-GAAP measure) | $27,488 | $30,618 |
| Basic and diluted Operating Results per share (a non-GAAP measure) | $2.12 | $2.37 |
| Shares used in computation - basic and diluted | 12,979 | 12,894 |
33
2022 Third Quarter Compared to the 2021 Third Quarter Results
The following table summarizes financial data by segment for the periods indicated and reconciles the data to our consolidated financial statements (in thousands):
| Net operating revenue: | Three Months Ended September 30, 2022 | 2021 |
|---|---|---|
| Physical therapy operations | $119,447 | $115,399 |
| Industrial injury prevention services | 20,155 | 10,494 |
| Total Company | $139,602 | $125,893 |
| Gross profit: | ||
| Physical therapy operations | $22,379 | $27,123 |
| Industrial injury prevention services | 4,405 | 2,676 |
| Gross profit | $26,784 | $29,799 |
| Total Assets: | ||
| Physical therapy operations | $432,683 | $583,785 |
| Industrial injury prevention services | 367,025 | 46,313 |
| Total Company | $799,708 | $630,098 |
Revenue
Reported total revenue for the 2022 Third Quarter was $139.6 million, an increase of 10.9% as compared to $125.9 million for the 2021 Third Quarter. See table below for a detail of reported total revenue (in thousands):
| Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Revenue related to Mature Clinics | $106,485 | $106,631 |
| Revenue related to 2022 Clinic Additions | 3,707 | - |
| Revenue related to 2021 Clinic Additions | 6,481 | 4,869 |
| Revenue from clinics sold or closed in 2022 | 37 | 762 |
| Revenue from clinics sold or closed in 2021 | - | 65 |
| Net patient revenue from physical therapy operations | 116,710 | 112,327 |
| Other revenue | 753 | 759 |
| Revenue from physical therapy operations | 117,463 | 113,086 |
| Revenue - Management contracts | 1,984 | 2,313 |
| Revenue - Industrial injury prevention services | 20,155 | 10,494 |
| Total revenue | $139,602 | $125,893 |
Revenue from physical therapy operations increased $4.4 million, or 3.9%, to $117.5 million for the 2022 Third Quarter from $113.1 million for the 2021 Third Quarter. Net patient revenue related to clinics opened or acquired prior to 2021 and still in operation on September 30, 2022 (“Mature Clinics”) decreased slightly. Visits for Mature Clinics (same store) for the 2022 Third Quarter decreased by 1.5% as compared to the 2021 Third Quarter, while the net patient revenue per visit increased by 1.4%.
The average net patient revenue per visit was $104.01 for the 2022 Third Quarter, a $1.08 per visit increase from $102.93 for the 2021 Third Quarter. Total patient visits increased 2.8% to 1,122,070 for the 2022 Third Quarter from 1,091,329 for the 2021 Third Quarter. Net patient revenue is based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenue is determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
IIPS revenue was an all-time high and increased 92.1% to $20.2 million for the 2022 Third Quarter as compared to $10.5 million for the 2021 Third Quarter. Excluding $6.8 million of revenue related to the November 2021 IIPS Acquisition, IIPS revenue increased 27.1% in the 2022 Third Quarter as compared to the 2021 Third Quarter.
Revenue from management contracts was $2.0 million for the 2022 Third Quarter as compared to $2.3 million for the 2021 Third Quarter due to the termination of five management contracts.
Operating Cost
Total operating cost was $112.8 million for the 2022 Third Quarter, or 80.8% of total revenue, as compared to $96.1 million, or 76.3% of total revenue, for the 2021 Third Quarter. Operating cost related to Mature Clinics increased by $4.3 million, or 5.2%, for the 2022 Third Quarter compared to the 2021 Third Quarter. In addition, operating cost related to the IIPS business increased by $7.9 million of which $5.8 million related to our November 2021 IIPS Acquisition. See table below for a detail of operating cost (in thousands):
| Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Operating cost related to Mature Clinics | $86,177 | $81,911 |
| Operating cost related to 2022 Clinic Additions | 3,267 | - |
| Operating cost related to 2021 Clinic Additions | 5,366 | 3,748 |
| Operating cost related to clinics sold or closed in 2022 | 721 | 504 |
| Operating cost related to clinics sold or closed in 2021 | - | 69 |
| Operating cost related to physical therapy operations | 95,531 | 86,232 |
| Operating cost related to management contracts | 1,537 | 2,044 |
| Operating cost related to industrial injury prevention services | 15,750 | 7,818 |
| Total operating cost | $112,818 | $96,094 |
Each component of operating cost is discussed below:
Operating Cost—Salaries and Related Costs
Salaries and related costs, including physical therapy operations and the IIPS business, was 58.6% of net revenue for the 2022 Third Quarter versus 56.1% for the 2021 Third Quarter. Salaries and related costs for the physical therapy operations was $68.4 million in the 2022 Third Quarter, or 58.3% of physical therapy operations revenue, as compared to $62.5 million in the 2021 Third Quarter, or 55.3% of physical therapy operations revenue. Included in salaries and related costs for the physical therapy operations for the 2022 Third Quarter was $5.7 million related to 2022 and 2021 Clinic Additions. Adjusted for the salaries and related costs for clinics closed or sold in 2022 and 2021 of $0.1 million in the Third Quarter and $0.4 million in 2021 Third Quarter, salaries and related costs related to Mature Clinics increased by $2.9 million in the 2022 Third Quarter compared to the 2021 Third Quarter. Physical therapy total operating costs were $85.14 per visit in the 2022 Third Quarter as compared to $79.02 per visit in the 2021 Third Quarter, an increase of 7.7%. Physical therapy salaries and related costs were $60.99 per visit in the 2022 Third Quarter as compared to $56.63 per visit in the Third Quarter 2021, an increase of 7.7%, The cost increases are primarily due to continuing labor rate pressures and the inflationary economic environment.
Salaries and related costs for the IIPS business was $12.1 million in the 2022 Third Quarter, or 59.9% of IIPS revenue, as compared to $6.3 million in the 2021 Third Quarter, or 60.8% of IIPS revenue.
Operating Cost—Rent, Supplies, Contract Labor and Other
Rent, supplies, contract labor and other costs, including physical therapy operations and the IIPS business, was 21.3% of net revenue in the 2022 Third Quarter versus 19.3% in the 2021 Third Quarter. Rent, supplies, contract labor and other costs for the physical therapy operations was $25.7 million in the 2022 Third Quarter, or 21.9% of physical therapy operations revenue, as compared to $22.4 million in the 2021 Third Quarter, or 19.8% of physical therapy operations revenue. Included in rent, supplies, contract labor and other costs related to physical therapy operations for the 2022 Third Quarter was $2.8 million related to 2022 and 2021 Clinic Additions. Adjusted for the rent, supplies, contract labor and other costs for clinics related to the clinics closed or sold in 2022 and 2021 of $0.7 million in the 2022 Third Quarter and $0.2 million in the 2021 Third Quarter, rent, supplies, contract labor and other costs for Mature Clinics increased by $1.3 million in the 2022 Third Quarter compared to the 2021 Third Quarter. Rent, supplies, contract labor and other costs, related to management contracts decreased $0.1 million in the 2022 Third Quarter.
Rent, supplies, contract labor and other costs for the IIPS business was $3.7 million in the 2022 Third Quarter, or 18.6% of IIPS revenue, as compared to $1.4 million in the 2021 Third Quarter, or 13.7% of net IIPS revenue.
Operating Cost—Provision for Credit Losses
The provision for credit losses as a percentage of net revenue was 1.0% in the 2022 Third Quarter and 1.1% for the comparable period in 2021.
Our provision for credit losses for patient accounts receivable as a percentage of total patient accounts receivable was 5.62% on September 30, 2022, as compared to 5.64% on December 31, 2021. Our days’ sales outstanding were both 32 days on September 30, 2022, and December 31, 2021.
Gross Profit
Gross profit for the 2022 Third Quarter, was $26.8 million, as compared to $29.8 million for the 2021 Third Quarter. The gross profit percentage was 19.2% of total revenue for the 2022 Third Quarter as compared to 23.7% for the 2021 Third Quarter. The gross profit percentage for our physical therapy operations was 18.7% for the 2022 Third Quarter as compared to 23.7% for the 2021 Third Quarter. The gross profit percentage on management contracts was 22.5% for the 2022 Third Quarter as compared to 11.6% for the 2021 Third Quarter. The gross profit percentage for IIPS was 21.9% for the 2022 Third Quarter as compared to 25.5% for the 2021 Third Quarter. The IIPS margin in 2022 has been impacted by the lower margin profile of our November 2021 IIPS Acquisition. The table below details the gross profit (in thousands):
| Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Physical therapy operations | $21,932 | $26,854 |
| Management contracts | 447 | 269 |
| Industrial injury prevention services | 4,405 | 2,676 |
| Gross profit | $26,784 | $29,799 |
Corporate Office Cost
Corporate office costs were $11.9 million for the 2022 Third Quarter compared to $12.9 million for the 2021 Third Quarter. Corporate office costs were 8.5% of total revenue for the 2022 Third Quarter as compared to 10.2% for the 2021 Third Quarter. The decrease was primarily due to lower estimated bonus expense in the 2022 Third Quarter than the 2021 Third Quarter.
Operating Income
Operating income for the 2022 Third Quarter was $14.9 million and $16.9 million for 2021 Third Quarter. Operating income as a percentage of total revenue was 10.7% for the 2022 Third Quarter as compared to 13.4% for the 2021 Third Quarter.
Change in fair value of contingent earn-out consideration
During the 2022 Third Quarter, the Company revalued contingent earn-out consideration related to an acquisition, resulting in the elimination of a previously booked liability of $2.0 million.
Equity in earnings of unconsolidated affiliate
Through a subsidiary, we have a 49% joint venture interest in a company which provides physical therapy services for patients at hospitals. Since we are deemed to not have a controlling interest in the joint venture, our investment is accounted for using the equity method of accounting. The investment balance of this joint venture as of September 30, 2022, is $12.0 million. For the 2022 Third Quarter, we recognized income of $0.3 million on this 49% joint venture.
Change in Revaluation of Put-Right Liability
The gain on revaluation of put-right liability was $0.8 million for the 2022 Third Quarter. As part of the November 2021 IIPS Acquisition, we agreed to the potential future purchase of a separate company under the same ownership that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area. The owners have the right to put this transaction to us in approximately five years from November 2021, with such right having a $2.8 million value on September 30, 2022, as reflected on our consolidated balance sheet in Other long-term liabilities. The value of this right will continue to be adjusted in future periods, as appropriate.
Interest expense – debt and other, net
For the 2022 Third Quarter, the interest expense on debt and other, primarily from our $150 million term loan entered into in June 2022, details of which are disclosed within LIQUIDITY AND CAPITAL RESOURCES below, amounted to $2.0 million. See discussion of Other Comprehensive Income below. Interest expense, primarily from the Company’s revolving line of credit, was $0.3 million for the 2021 Third Quarter.
Provision for Income Taxes
The provision for income tax was $3.2 million for the 2022 Third Quarter and $3.8 million for the 2021 Third Quarter. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest (effective tax rate) was 25.2% for the 2022 Third Quarter and 27.6% for the 2021 Third Quarter. The current quarter included an adjustment to the tax provision based on revised estimates on certain non-deductible items (see computation of 2022 Nine Month tax rate in next section). See table below detailing calculation of the provision for income taxes as a percentage of income before taxes less net income attributable to non-controlling interest ($ in thousands):
| Three Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Income before taxes | $16,036 | $17,938 |
| Less: net income attributable to non-controlling interest: | ||
| Redeemable non-controlling interest - temporary equity | (2,037) | (2,605) |
| Non-controlling interest - permanent equity | (1,227) | (1,509) |
| $(3,264) | $(4,114) | |
| Income before taxes less net income attributable to non-controlling interest | $12,772 | $13,824 |
| Provision for income taxes | $3,215 | $3,815 |
| Percentage | 25.2% | 27.6% |
Net Income Attributable to Non-controlling Interest
Net income attributable to redeemable non-controlling interest (temporary equity) was $2.0 million for the 2022 Third Quarter and $2.6 million for the 2021 Third Quarter. Net income attributable to non-controlling interest (permanent equity) was $1.2 million for the 2022 Third Quarter and $1.5 million for the 2021 Third Quarter.
Other Comprehensive Gain
We entered into an interest rate swap agreement in May 2022, which has a $150 million notional value, a maturity date of June 30, 2027 and was effective on June 30, 2022. Beginning in July 2022, we pay a fixed rate of interest of 2.815% on a quarterly basis. The total interest rate in any period will also include an applicable margin based on our consolidated leverage ratio. Currently, our interest rate including the applicable margin is 4.665%. Unrealized gains and losses related to the fair value of the interest rate swap are recorded to accumulated other comprehensive income (loss), net of tax. The fair value of the interest rate swap on September 30, 2022, was $5.9 million, of which $1.9 million has been included within Other current assets and $4.0 million has been included in Other assets in the accompanying Consolidated Balance Sheet. The impact of the interest rate swap on the accompanying Consolidated Statements of Comprehensive Income was an unrealized gain of $4.8 million, net of tax, for the 2022 Third Quarter.
2022 Nine Months Compared to 2021 Nine Months Results
The following table summarizes financial data by segment for the periods indicated and reconciles the data to our consolidated financial statements (in thousands):
| Net operating revenue: | Nine Months Ended September 30, 2022 | 2021 |
|---|---|---|
| Physical therapy operations | $353,302 | $334,652 |
| Industrial injury prevention services | 58,660 | 30,537 |
| Total Company | $411,962 | $365,189 |
| Gross profit: | ||
| Physical therapy operations | $71,513 | $82,058 |
| Industrial injury prevention services | 12,680 | 7,941 |
| Gross profit | $84,193 | $89,999 |
| Total Assets: | ||
| Physical therapy operations | $432,683 | $583,785 |
| Industrial injury prevention services | 367,025 | 46,313 |
| Total Company | $799,708 | $630,098 |
Revenue
Reported total revenue for the 2022 Nine Months was $412.0 million, an increase of 12.8% as compared to $365.2 million for the 2021 Nine Months. See table below for a detail of reported total revenue (in thousands):
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Revenue related to Mature Clinics | $317,514 | $314,969 |
| Revenue related to 2022 Clinic Additions | 7,019 | - |
| Revenue related to 2021 Clinic Additions | 18,827 | 7,334 |
| Revenue from clinics sold or closed in 2022 | 1,084 | 2,058 |
| Revenue from clinics sold or closed in 2021 | - | 458 |
| Net patient revenue from physical therapy operations | 344,444 | 324,819 |
| Other revenue | 2,523 | 2,222 |
| Revenue from physical therapy operations | 346,967 | 327,041 |
| Revenue - Management contracts | 6,335 | 7,611 |
| Revenue - Industrial injury prevention services | 58,660 | 30,537 |
| Total revenue | $411,962 | $365,189 |
Revenue from physical therapy operations increased $19.9 million, or 6.1%, to $347.0 million for the 2022 Nine Months from $327.0 million for the 2021 Nine Months.
The average net patient revenue per visit was $103.40 for the 2022 Nine Months as compared to $104.00 for the 2021 Nine Months. Total patient visits increased 6.7% to 3,331,143 for the 2022 Nine Months from 3,123,187 for the 2021 Nine Months. Net patient revenue is based on established billing rates less allowances for patients covered by contractual programs and workers’ compensation. Net patient revenue is determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under contractual programs and workers’ compensation are based on predetermined rates and are generally less than the established billing rates.
Net patient revenue related to Mature Clinics increased $2.5 million, or 0.8%, to $317.5 million for the 2022 Nine Months compared to $315.0 million for the 2021 Nine Months. Visits for Mature Clinics (same store) for the 2022 Nine Months increased 1.5% as compared to the 2021 Nine Months. The increase in visits was partially offset by a 0.7% reduction in the net patient revenue per visit.
IIPS services revenue increased 92.1% to $58.7 million for the 2022 Nine Months as compared to $30.5 million for the 2021 Nine Months. Excluding $20.5 million of revenue related to the November 2021 IIPS Acquisition, IIPS revenue increased 25.0% in the 2022 Nine Months as compared to the 2021 Nine Months.
Revenue from management contract revenue decreased 16.8% to $6.3 million for the 2022 Nine Months as compared to $7.6 million for the 2021 Nine Months due to the termination of certain management contracts.
Operating Cost
Total operating cost was $327.8 million for the 2022 Nine Months, or 79.6% of total revenue, as compared to $275.2 million, or 75.4% of total revenue, for the 2021 Nine Months. Operating cost related to Mature Clinics increased by $15.9 million for the 2022 Nine Months compared to the 2021 Nine Months. In addition, operating cost related to the IIPS business increased by $23.4 million of which $17.0 million related to the November 2021 IIPS Acquisition. See table below for a detail of operating cost (in thousands):
| Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Operating cost related to Mature Clinics | $253,899 | $237,982 |
| Operating cost related to 2022 Clinic Additions | 6,271 | - |
| Operating cost related to 2021 Clinic Additions | 15,393 | 5,877 |
| Operating cost related to clinics sold or closed in 2022 | 1,233 | 1,733 |
| Operating cost related to clinics sold or closed in 2021 | 2 | 510 |
| Operating cost related to physical therapy operations | 276,798 | 246,102 |
| Operating cost related to management contracts | 4,991 | 6,492 |
| Operating cost related to industrial injury prevention services | 45,980 | 22,596 |
| Total operating cost | $327,769 | $275,190 |
Each component of operating cost is discussed below:
Operating Cost—Salaries and Related Costs
Salaries and related costs, including physical therapy operations and the IIPS business, was 57.5% of net revenue for the 2022 Nine Months versus 55.6% for the 2021 Nine Months. Salaries and related costs for the physical therapy operations was $197.7 million in the 2022 Nine Months, or 57.0% of physical therapy operations revenue, as compared to $178.6 million in the 2021 Nine Months, or 54.6% of physical therapy operations revenue. Included in salaries and related costs for the physical therapy operations for the 2022 Nine Months was $13.8 million related to 2022 and 2021 Clinic Additions. Adjusted for the salaries and related costs for clinics closed or sold in 2022 and 2021 of $0.8 million in the 2022 Nine Months and $1.4 million in 2021 Nine Months, salaries and related costs related to Mature Clinics increased by $9.7 million in the 2022 Nine Months compared to the 2021 Nine Months. Salaries and related costs related to management contracts decreased by $1.3 million for the 2022 Nine Months. As previously mentioned, the Company is experiencing pressure on labor rates and other costs due to the inflationary economic environment.
Salaries and related costs for the IIPS business was $34.8 million in the 2022 Nine Months, or 59.3% of IIPS revenue, as compared to $18.8 million in the 2021 Nine Months, or 61.8% of IIPS revenue.
Operating Cost—Rent, Supplies, Contract Labor and Other
Rent, supplies, contract labor and other costs, including physical therapy operations and the IIPS business, was 21.0% of net revenue in the 2022 Nine Months versus 18.6% in the 2021 Nine Months. Rent, supplies, contract labor and other costs for the physical therapy operations was $75.0 million in the 2022 Nine Months, or 21.6% of physical therapy operations revenue, as compared to $63.5 million in the 2021 Nine Months, or 19.4% of physical therapy operations revenue. Included in rent, supplies, contract labor and other costs related to physical therapy operations for the 2022 Nine Months was $7.5 million related to 2022 and 2021 Clinic Additions. Adjusted for the rent, supplies, contract labor and other costs for clinics related to the clinics closed or sold in 2022 and 2021 of $0.4 million in the 2022 Nine Months and $0.8 million in the 2021 Nine Months, rent, supplies, contract labor and other costs for Mature Clinics increased by $6.4 million in the 2022 Nine Months compared to the 2021 Nine Months. Rent, supplies, contract labor and other costs, related to management contracts decreased $0.2 million in the 2022 Nine Months.
Rent, supplies, contract labor and other costs for the IIPS business was $11.1 million in the 2022 Nine Months, or 18.9% of IIPS revenue, as compared to $3.7 million in the 2021 Nine Months, or 12.2% of net IIPS revenue.
Operating Cost—Provision for Credit Losses
The provision for credit losses as a percentage of net revenue was 1.0% in the 2022 Nine Months and 1.1% for the comparable period in 2021.
Our provision for credit losses for patient accounts receivable as a percentage of total patient accounts receivable was 5.62% on September 30, 2022, as compared to 5.64% at December 31, 2021. Our days’ sales outstanding were 32 days at September 30, 2022 and December 31, 2021.
Gross Profit
Gross profit for the 2022 Nine Months was $84.2 million, a decrease of $5.8 million, or 6.5%, as compared to $90.0 million for the 2021 Nine Months. The gross profit percentage was 20.4% of total revenue for the 2022 Nine Months as compared to 24.6% for the 2021 Nine Months. The gross profit percentage for our physical therapy operations was 20.2% for the 2022 Nine Months as compared to 24.7% for the 2021 Nine Months. The gross profit percentage on management contracts was 21.2% for the 2022 Nine Months as compared to 14.7% for the 2021 Nine Months. The gross profit percentage for the IIPS business was 21.6% for the 2022 Nine Months as compared to 26.0% for the 2021 Nine Months. The IIPS margin in 2022 has been impacted by the lower margin profile of our November IIPS Acquisition. The table below details the gross profit (in thousands):
| Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Physical therapy operations | $70,169 | $80,939 |
| Management contracts | 1,344 | 1,119 |
| Industrial injury prevention services | 12,680 | 7,941 |
| Gross profit | $84,193 | $89,999 |
Corporate Office Cost
Corporate office costs were $34.2 million for the 2022 Nine Months compared to $35.8 million for the 2021 Nine Months. Corporate office costs were 8.3% of total revenue for the 2022 Nine Months as compared to 9.8% for the 2021 Nine Months. The decrease was primarily due to lower estimated bonus expense in the 2022 Nine Months than the 2021 Nine Months.
Operating Income
Operating income for the 2022 Nine Months was $50.0 million and $54.2 million for 2021 Nine Months. Operating income as a percentage of total revenue was 12.1% for the 2022 Nine Months as compared to 14.8% for the 2021 Nine Months.
Equity in earnings of unconsolidated affiliate
Through a subsidiary, we have a 49% joint venture interest in a company which provides physical therapy services for patients at hospitals. Since we are deemed to not have a controlling interest in the joint venture, our investment is accounted for using the equity method of accounting. The investment balance of this joint venture as of September 30, 2022, is $12.0 million. For the 2022 Nine Months, we recognized income of $1.0 million on this 49% joint venture.
Change in fair value of contingent earn-out consideration
During the 2022 Nine Months, the Company revalued contingent earn-out consideration related to an acquisition, resulting in the elimination of a previously booked liability of $2.0 million.
Change in Revaluation of Put-Right Liability
For the 2022 Nine Months, we recorded a gain on the revaluation of the put-right liability of $0.8 million. As part of the November 2021 IIPS Acquisition, we agreed to the potential future purchase of a separate company under the same ownership that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area. The owners have the right to put this transaction to us in approximately five years, with such right having a $2.8 million value on September 30, 2022, as reflected on our consolidated balance sheet in Other long-term liabilities. The value of this right will continue to be adjusted in future periods, as appropriate.
Interest expense – debt and other, net
For the 2022 Nine Months, the interest expense on debt and other, primarily from our $150 million term loan entered into in June 2022, details of which are disclosed withing LIQUIDITY AND CAPITAL RESOURCES, amounted to $3.5 million. See discussion of Other Comprehensive Income below. Interest expense, primarily from the Company’s revolving line of credit was $0.8 million for the 2021 Nine Months.
Provision for Income Taxes
The provision for income tax was $11.0 million for the 2022 Nine Months and $11.3 million for the 2021 Nine Months. The provision for income tax as a percentage of income before taxes less net income attributable to non-controlling interest (effective tax rate) was 27.0% for both the 2022 Nine Months and the 2021 Nine Months. See table below ($ in thousands):
| For the Nine Months Ended September 30, 2022 | September 30, 2021 | |
|---|---|---|
| Income before taxes | $51,011 | $54,807 |
| Less: net income attributable to non-controlling interest: | ||
| Redeemable non-controlling interest - temporary equity | (7,220) | (8,669) |
| Non-controlling interest - permanent equity | (3,288) | (4,194) |
| $(10,508) | $(12,863) | |
| Income before taxes less net income attributable to non controlling interest | $40,503 | $41,944 |
| Provision for income taxes | $10,952 | $11,326 |
| Percentage | 27.0% | 27.0% |
Net Income Attributable to Non-controlling Interest
Net income attributable to redeemable non-controlling interest (temporary equity) was $7.2 million for the 2022 Nine Months and $8.7 million for the 2021 Nine Months. Net income attributable to non-controlling interest (permanent equity) was $3.3 million for the 2022 Nine Months and $4.2 million for the 2021 Nine Months.
Other Comprehensive Income
The impact of the interest rate swap (described within LIQUIDITY AND CAPITAL RESOURCES below) on the accompanying Consolidated Statements of Comprehensive Income was an unrealized gain of $4.4 million, net of tax, for the 2022 Nine Months.
LIQUIDITY AND CAPITAL RESOURCES
We believe that our business has sufficient cash to allow us to meet our short-term cash requirements. On September 30, 2022 and December 31, 2021, we had $37.9 million and $28.6 million, respectively, in cash. We believe that our cash and cash equivalents and availability under our Credit Facilities are sufficient to fund the working capital needs of our operating subsidiaries through at least September 30, 2023.
Cash and cash equivalents increased by $9.4 million from December 31, 2021 to September 30, 2022. During the 2022 Nine Months, $41.2 million was provided by operations and $36.0 million, net of payments, from proceeds on our Credit Agreement (described below). The major uses of cash for investing and financing activities included: distributions to non-controlling interests inclusive of those classified as redeemable non-controlling interest ($11.8 million), dividends paid to our shareholders ($16.0 million), purchase of business and non-controlling interest ($32.9 million), and purchase of fixed assets ($7.3 million).
On June 17, 2022, we entered into the Third Amended and Restated Credit Agreement (the “Credit Agreement”) among Bank of America, N.A., as administrative agent (“Administrative Agent”) and others.
The Credit Agreement, which matures on June 17, 2027, provides for loans in an aggregate principal amount of $325 million. Such loans will be available through the following facilities (collectively, the “Senior Credit Facilities”):
1) Revolving Facility: $175 million, five-year, revolving credit facility (“Revolving Facility”), which includes a $12 million sublimit for the issuance of standby letters of credit and a $15 million sublimit for swingline loans (each, a “Swingline Loan”).
2) Term Facility: $150 million term loan facility (the “Term Facility”). The Term Facility amortizes in quarterly installments of: (a) 0.625% in each of the first two years, (b) 1.250% in the third and fourth year, and (c) 1.875% in the fifth year of the Credit Agreement. The remaining outstanding principal balance of all term loans is due on the maturity date.
The proceeds of the Revolving Facility shall be used by us for working capital and other general corporate purposes of the Company and its subsidiaries, including to fund future acquisitions and invest in growth opportunities. The proceeds of the Term Facility were used by us to refinance the indebtedness outstanding under the Second Amended and Restated Credit Agreement, to pay fees and expenses incurred in connection with the loan facilities transactions, for working capital and other general corporate purposes of our Company and its subsidiaries.
We will be permitted to increase the Revolving Facility and/or add one or more tranches of term loans in an aggregate amount not to exceed the sum of (i) $100 million plus (ii) an unlimited additional amount, provided that (in the case of clause (ii)), after giving effect to such increases, the pro forma Consolidated Leverage Ratio (as defined in the Credit Agreement) would not exceed 2.0:1.0, and the aggregate amount of all incremental increases under the Revolving Facility does not exceed $50,000,000.
The interest rates per annum applicable to the Senior Credit Facilities (other than in respect of Swingline Loans) will be Term SOFR as defined in the agreement plus an applicable margin or, at our option, an alternate base rate plus an applicable margin. Currently, our interest rate including the applicable margin is 4.665%. Interest is payable at the end of the selected interest period but no less frequently than quarterly and on the date of maturity.
We will also pay to the Administrative Agent, for the account of each lender under the Revolving Facility, a commitment fee equal to the actual daily excess of each lender’s commitment over its outstanding credit exposure under the Revolving Facility (“unused fee”). We may prepay and/or repay the revolving loans and the term loans, and/or terminate the revolving loan commitments, in whole or in part, at any time without premium or penalty, subject to certain conditions.
The Credit Agreement contains customary covenants limiting, among other things, the incurrence of additional indebtedness, the creation of liens, mergers, consolidations, liquidations and dissolutions, sales of assets, dividends and other payments in respect of equity interests, acquisitions, investments, loans and guarantees, subject, in each case, to customary exceptions, thresholds and baskets. The Credit Agreement includes certain financial covenants which include the Consolidated Fixed Charge Coverage Ratio and the Consolidated Leverage Ratio, as defined in the Credit Agreement. The Credit Agreement also contains customary events of default.
Our obligations under the Credit Agreement are guaranteed by its wholly owned material domestic subsidiaries (each, a “Guarantor”), and our obligations and any Guarantors are secured by a perfected first priority security interest in substantially all of the existing and future personal property of our Company and each Guarantor, subject to certain exceptions.
In May 2022, we entered into an interest rate swap agreement, effective on June 30, 2022, with Bank of America, N.A, which has a $150 million notional value, and a maturity date of June 30, 2027. Beginning in July 2022, we make interest payments based on the 1-month SOFR rate (“variable rate payment”) and receive or pay the differential between the variable rate payment and the fixed 2.815% SOFR rate on a monthly basis. Also included in the total interest payment in any period is an applicable margin based on our consolidated leverage ratio.
We designated the interest rate swap as a cash flow hedge and structured it to be highly effective. Consequently, unrealized gains and losses related to the fair value of the interest rate swap are recorded to accumulated other comprehensive income (loss), net of tax.
On September 30, 2022, $150.0 million was outstanding on the Term Loan and the Revolving Facility remains available resulting in $175.0 million of availability. As of September 30, 2022, we were in compliance with all of the covenants thereunder. Through the date of this report, we have drawn $5.0 million on the Revolving Facility.
On March 31, 2022, we acquired a 70% interest in a six-clinic physical therapy practice. The practice’s owners retained 30% of the equity interests. The purchase price for the 70% equity interest was approximately $11.5 million, of which $11.2 million was paid in cash and $0.3 million is in the form of a note payable. The note accrues interest at 3.5% per annum and the principal and interest are payable on March 31, 2024.
On August 31, 2022, we acquired a 70% interest in a six-clinic physical therapy practice. The practice’s owners retained 30% of the equity interests. The purchase price for the 70% equity interest was approximately $3.5 million, of which $3.3 million was paid in cash and $0.2 million in the form of a note payable. The note accrues interest at 5.5% per annum and the principal and interest are payable on August 31, 2024.
On September 30, 2022, we acquired an 80% interest in a two-clinic physical therapy practice. The practice’s owners retained 20% of the equity interests. The purchase price for the 80% equity interest was approximately $4.2 million, of which $3.9 million was paid in cash and $0.3 million in the form of a note payable. The note accrues interest at 5.5% per annum and the principal and interest are payable on September 30, 2024.
On December 31, 2021, we acquired a 75% interest in a three-clinic physical therapy practice with the practice founder retaining 25%. The purchase price for the 75% interest was approximately $3.7 million, of which $3.5 million was paid in cash and $0.2 million in the form of a note payable. The note accrues interest at 3.25% per annum and the principal and interest are payable on December 31, 2023.
On November 30, 2021, we acquired an approximate 70% interest in a leading provider of industrial injury prevention services. The previous owners retained the remaining interest. The initial purchase price for the 70% equity interest, not inclusive of the $2.0 million contingent payment in conjunction with the acquisition if specified future operational objectives are met, was approximately $63.2 million, of which $62.2 million was paid in cash, and $1.0 million is in the form of a note payable. The note accrues interest at 3.25% and the principal and interest is payable on November 30, 2023. The business generates approximately $27.0 million in annual revenue at a margin of approximately 20%. As part of the transaction, we also agreed to the future purchase of a separate company under the same ownership that provides physical therapy and rehabilitation services to hospitals and other ancillary providers in a distinct market area. The current owners have the right to put this transaction to us in approximately five years, with such put right having an initial $3.5 million fair value on June 30, 2022, as reflected on our consolidated balance sheet in Other long-term liabilities. The value of this right will be adjusted in future periods, as appropriate, with any change in fair value reflected in our consolidated statement of income.
On September 30, 2021, we acquired a company that specializes in return-to-work and ergonomic services, among other offerings. The business generates more than $2.0 million in annual revenue. We acquired the company’s assets at a purchase price of approximately $3.3 million (which includes the obligation to pay an amount up to $0.6 million in contingent payment consideration in conjunction with the acquisition if specified future operational objectives are met) and contributed those assets to our IIPS subsidiary. The initial purchase price, not inclusive of the $0.6 million contingent payment, was approximately $2.7 million, of which $2.4 million was paid in cash, and $0.3 million is in the form of a note payable. The note accrues interest at 3.25% per annum and the principal and interest are payable on September 30, 2023.
On June 30, 2021, we acquired a 65% interest in an eight-clinic physical therapy practice with the practice founders retaining 35%. The purchase price was approximately $10.3 million, of which $9.0 million was paid in cash, $1.0 million was payable based on the achievement of certain business criteria and $0.3 million is in the form of a note payable. The business criteria were met and accordingly $1.0 million was paid in July 2022. The note accrues interest at 3.25% per annum and the principal and interest are payable on June 30, 2023. Additionally, we have an obligation to pay an additional amount up to $0.8 million in contingent payment consideration in conjunction with the acquisition if specified future operational objectives are met. We recorded acquisition-date fair value of this contingent liability based on the likelihood of the contingent earn-out payment. The earn-out payment will subsequently be remeasured to fair value each reporting date.
On March 31, 2021, the Company acquired a 70% interest in a five-clinic physical therapy practice with the practice founders retaining 30%. When acquired, the practice was developing a sixth clinic which has been completed. The purchase price for the 70% interest was approximately $12.0 million, of which $11.7 million was paid in cash and $0.3 million is in the form of a note payable. The note accrues interest at 3.25% per annum and the principal and interest are payable on March 31, 2023.
On March 27, 2020, in response to the COVID-19 pandemic, the federal government approved the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”). The CARES Act provided waivers, reimbursement, grants and other funds to assist health care providers during the COVID-19 pandemic, including $100.0 billion in appropriations for the Public Health and Social Services Emergency Fund, also referred to as the Provider Relief Fund, to be used for preventing, preparing, and responding to the coronavirus, and for reimbursing eligible health care providers for lost revenues and health care related expenses that are attributable to COVID-19.
The CARES Act allowed for qualified healthcare providers to receive advanced payments under the Medicare Accelerated and Advance Payment Program (“MAAPP Funds”) during the COVID-19 pandemic. Under this program, healthcare providers could choose to receive advanced payments for future Medicare services provided. We applied for and received approval from Centers for Medicare & Medicaid Services (“CMS”) in April 2020. We recorded the $14.1 million in advance payments received as a liability. During the 2021 First Quarter, we repaid the MAAPP Funds of $14.1 million rather than applying them to future services performed.
Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We have from time to time purchased the non-controlling interests of limited partners in our Clinic Partnerships. We may purchase additional non-controlling interests in the future. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Any large acquisition would likely require financing.
We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting payor credentialing approval initially may be delayed for a relatively short transition period. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the accounts receivable has been outstanding for at least 120 days.
We generally enter into various notes payable as a means of financing our acquisitions. Our outstanding notes payable as of September 30, 2022 relate to certain of the acquisitions of businesses and purchases of redeemable non-controlling interest that occurred in 2018 through September 2022. Typically, the notes are payable over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 5.5% per annum, subject to adjustment. At September 30, 2022, the balance on these notes payable was $5.5 million. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities.
In conjunction with the above-mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after a specified date that is typically between three and five years from the acquisition date, we have agreed to certain contractual provisions which enable such minority partners to exercise their right to trigger our repurchase of that partner’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.
As of September 30, 2022, we have accrued $7.9 million related to credit balances due to patients and payors. This amount is expected to be paid in the next twelve months.
From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). Our Amended Credit Agreement permits share repurchases of up to $15,000,000, subject to compliance with covenants. We are required to retire shares purchased under the March 2009 Authorization.
There is no expiration date for the share repurchase program. As of September 30, 2022, there are currently an additional estimated 197,316 (based on the closing price of $76.02 on September 30, 2022) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2022.
FACTORS AFFECTING FUTURE RESULTS
The risks related to our business and operations include:
- the multiple effects of the impact of public health crises and epidemics/pandemics, such as the novel strain of COVID-19 and its variants, for which the total financial magnitude cannot be currently estimated;
- changes in Medicare rules and guidelines and reimbursement or failure of our clinics to maintain their Medicare certification and/or enrollment status;
- revenue we receive from Medicare and Medicaid being subject to potential retroactive reduction;
- changes in reimbursement rates or payment methods from third party payors including government agencies, and changes in the deductibles and co-pays owed by patients;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- the impact of COVID-19 related vaccination and/or testing mandates at the federal, state and/or local level, which could have an adverse impact on staffing, revenue, costs and the results of operations;
- changes as the result of government enacted national healthcare reform;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor inspections, reviews, investigations and audits, which may result in sanctions or reputational harm and increased costs;
- revenue and earnings expectations;
- some of our acquisition agreements contain contingent consideration, the value of which may impact future financial results;
- one of our acquisition agreements includes a Put Right for a potential purchase of a company and we may or may not have the capital necessary to satisfy this obligation;
- legal actions, which could subject us to increased operating costs and uninsured liabilities;
- general economic conditions, including but not limited to inflationary and recessionary periods;
- availability and cost of qualified physical therapists;
- personnel productivity and hiring, training and retaining key personnel;
- competitive environment in the IIPS business, which could result in the termination or nonrenewal of contractual service arrangements and other adverse financial consequences for that service line;
- acquisitions, and the successful integration of the operations of the acquired businesses;
- impact on the business and cash reserves resulting from retirement or resignation of key partners and resulting purchase of their non-controlling interest (minority interests);
- maintaining our information technology systems with adequate safeguards to protect against cyber-attacks;
- a security breach of our or our third party vendors’ information technology systems may subject us to potential legal action and reputational harm and may result in a violation of the Health Insurance Portability and Accountability Act of 1996 of the Health Information Technology for Economic and Clinical Health Act;
- maintaining clients for which we perform management and other services, as a breach or termination of those contractual arrangements by such clients could cause operating results to be less than expected;
- maintaining adequate internal controls;
- our business depends upon hiring, training and retaining qualified personnel;
- maintaining necessary insurance coverage;
- availability, terms, and use of capital; and
- weather and other seasonal factors.
In addition to the above, see Risk Factors in Part I - Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2021 and in Part II – Item 1A of this report.
Forward-Looking Statements
We make statements in this report that are considered to be forward-looking statements within the meaning given such term under Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements contain forward-looking information relating to the financial condition, results of operations, plans, objectives, future performance and business of our Company. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to the risks listed above.
Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see the other sections of this report and our other periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement may no longer be accurate.
Market risk
As filed, 1,247 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to certain market risks during the ordinary course of business due to adverse changes in interest rates. The exposure to interest rate risk primarily results from the Company’s variable-rate borrowing. The Company may elect to use derivative financial instruments to manage risks from fluctuations in interest rates. The Company does not purchase or hold derivatives for trading or speculative purposes. Fluctuations in interest rates can be volatile and the Company’s risk management activities do not eliminate these risks.
In May 2022, we entered into an interest rate swap agreement, effective on June 30, 2022, which has a $150 million notional value, and a maturity date of June 30, 2027. Beginning in July 2022, we receive 1-month SOFR, and pay a fixed rate of interest of 2.815% plus an additional margin on a quarterly basis. The total interest rate in any period will also include an applicable margin based on our Consolidated Leverage Ratio.
We designated the interest rate swap as a cash flow hedge and structured it to be highly effective. Consequently, unrealized gains and losses related to the fair value of the interest rate swap are recorded to accumulated other comprehensive income (loss), net of tax.
Controls and procedures
As filed, 1,386 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
(a) Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.
(b) Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Risk factors
As filed, 5,992 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
Our debt and financial obligations could adversely affect our financial condition, our ability to obtain future financing, and our ability to operate our business.
We have outstanding debt obligations that could adversely affect our financial condition and limit our ability to successfully implement our business strategy. Furthermore, from time to time, we may need additional financing to support our business and pursue our business strategy, including strategic acquisitions. Our ability to obtain additional financing, if and when required, will depend on investor demand, our operating performance, the condition of the capital markets, and other factors. We cannot provide assurances that additional financing will be available to us on favorable terms when required, or at all.
Our loan agreements contain certain restrictions and requirements that among other things:
- require us to maintain a quarterly fixed charge coverage ratio and minimum working capital ratio;
- limit our ability to obtain additional financing in the future for working capital, capital expenditures and acquisitions, to fund growth or for general corporate purposes;
- limit our future ability to refinance our indebtedness on terms acceptable to us or at all;
- limit our flexibility in planning for or reacting to changes in our business and market conditions or in funding our strategic growth plan; and
- impose on us financial and operational restrictions.
Our ability to meet our debt service obligations will depend on our future performance, which will be affected by the other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2021, filed on March 1, 2022. If we do not generate enough cash flow to pay our debt service obligations, we may be required to refinance all or part of our existing debt, sell our assets, borrow more money or raise equity. There is no guarantee that we will be able to take any of these actions on a timely basis, on terms satisfactory to us, or at all.
If we fail to satisfy our debt service obligations or the other restrictions and requirements in our loan agreements, we could be in default. Unless cured or waived, a default would permit lenders to accelerate the maturity of the debt under the credit agreement and to foreclose upon the collateral securing the debt.
Our outstanding loans bear interest at variable rates. In response to the variable rates, we entered into an interest rate swap agreement. We are exposed to certain market risks during the ordinary course of business due to adverse changes in interest rates. The exposure to interest rate risk primarily results from our variable-rate borrowing. Fluctuations in interest rates can be volatile and the Company’s risk management activities do not eliminate these risks. In May 2022, we entered into an interest rate swap agreement to manage these risks. While intended to reduce the effects of fluctuations in these prices and rates, these transactions may limit our potential gains or expose us to losses. If our counterparties to such transactions or the sponsors fail to honor their obligations due to financial distress, we would be exposed to potential losses or the inability to recover anticipated gains from these transactions.
Our business depends upon hiring, training and retaining qualified employees.
Our workforce costs represent our largest operating expense, and our ability to meet our labor needs while controlling labor costs is subject to numerous external factors, including market pressures with respect to prevailing wage rates and unemployment levels. We compete with rehabilitation companies and other businesses for many of our clinical and non-clinical employees, and turnover in these positions can lead to increased training and retention costs, particularly in a competitive labor market. We cannot be assured that we can continue to hire, train and retain qualified employees at current wage rates since we operate in a competitive labor market, and there are currently significant inflationary and other pressures on wages. If we are unable to hire, properly train and retain qualified employees, we could experience higher employment costs and reduced revenues, which could adversely affect our earnings.
Some of our acquisition agreements contain contingent consideration, the value of which may impact future financial results.
Some of our acquisition agreements include contingent earn-out consideration, the fair value of which is estimated as of the acquisition date based on the present value of the expected contingent payments as determined using weighted probabilities of possible future payments. These fair value estimates contain unobservable inputs and estimates that could materially differ from the actual future results. The fair value of the contingent earn-out consideration could increase or decrease as applicable. Changes in the fair value of contingent earn-outs will be reflected in our results of operations in the period in which they are recognized, the amount of which may be material and cause volatility in our operating results.
One of our acquisition agreements contains a Put Right related to a potential future purchase of a majority Interest In a separate company.
One of our acquisition agreements includes a Put Right for the potential future purchase of a majority interest in a separate company at a purchase price which is derived based on a specified multiple of the separate company’s historical earnings. The exercise of the Put Right is outside of our control. In the event the Put Right is triggered, we are required to purchase the aforementioned equity interest at the calculated purchase price described above. The resulting purchase price may be greater than the fair value of such equity interests at the time, and we may or may not have the capital necessary to satisfy such contractual purchase obligation, in which case we could be in breach.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $139.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $412.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Gross profit | 3 months2022-07-01 to 2022-09-30 | $26.8m | us-gaap:GrossProfit |
| Gross profit | 9 months2022-01-01 to 2022-09-30 | $84.2m | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $11.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $34.2m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | $14.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | $50.0m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $3.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $11.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $9.6m | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | $29.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $0.72 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | $2.27 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $0.72 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | $2.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 13,001,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 12,979,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $41.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $7.3m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months2022-01-01 to 2022-09-30 | $16.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | At period end2022-09-30 | $37.9m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $112.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $799.7m | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $81.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $332.9m | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $146.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-09-30 | $7.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2022-09-30 | $317.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001140361-22-040455. Last ingested by Listed: Nov 14, 2026, 13:45 ET. Listed shows no prices and gives no investment advice.